Rationality of Empirical Antibiotic Prescribing and Its Association with Length of Hospital Stay in Patients with Severe COVID-19
Abstract
Excessive empirical antibiotic prescribing during the COVID-19 pandemic raised concerns regarding antimicrobial resistance, particularly in hospitals with limited microbiological diagnostic capacity. This study aimed to describe empirical antibiotic prescribing patterns, evaluate the rationality of antibiotic use, and examine its association with length of hospital stay among patients with severe-to-critical COVID-19 at a private secondary-care hospital in Batam City, Indonesia. A retrospective observational study was conducted using the medical records of 120 patients admitted between April and June 2022. Antibiotic rationality was evaluated according to drug selection, dose, route of administration, dosing interval, and treatment duration using the local Hospital Antibiotic Use Guideline, the Indonesian COVID-19 Management Guideline, and relevant international guidelines. Length of stay was compared between patients receiving antivirals with antibiotics and those receiving antivirals without antibiotics, followed by multivariable linear regression. Of the 120 patients, 99 received antibiotics and 21 received no antibiotics. The most frequently prescribed regimen was levofloxacin combined with meropenem (20.83%), followed by levofloxacin monotherapy (18.33%). Among antibiotic recipients, appropriateness was 64.6% for drug selection, 79.8% for dose, 96.0% for route of administration, 94.9% for dosing interval, and 100% for treatment duration. Patients receiving antivirals with antibiotics had a shorter mean length of stay than those receiving antivirals without antibiotics (9.2 ± 2.4 versus 12.8 ± 3.1 days; p = 0.002). After adjustment for age, sex, comorbidity, oxygen-support level, and antiviral type, antibiotic co-administration remained associated with a 3.6-day shorter hospital stay (adjusted β = −3.6; 95% CI, −4.8 to −2.3; p < 0.001). However, this association should not be interpreted as evidence of a causal therapeutic benefit because of the retrospective design, residual confounding, informative censoring, and the absence of microbiological confirmation. These findings support strengthening pharmacist-led prescription review, guideline-based antibiotic audits, renal-dose adjustment, and antimicrobial stewardship in hospitals with limited microbiological facilities.
Keywords
Full Text:
PDFReferences
F. Isbaniah and A. D. Susanto, “Pneumonia coronavirus disease 2019 (COVID-19),” Journal of the Indonesian Medical Association, vol. 70, no. 4, pp. 87–94, 2020. [Online]. Available: https://doi.org/10.47830/jinma-vol.70.4-2020-235
V. Bajaj, N. Gadi, A. P. Spihlman, S. C. Wu, C. H. Choi, and V. R. Moulton, “Aging, immunity, and COVID-19: How age influences the host immune response to coronavirus infections,” Frontiers in Physiology, vol. 11, art. no. 571416, 2021. [Online]. Available: https://doi.org/10.3389/fphys.2020.571416
Z. Karami et al., “Few bacterial co-infections but frequent empiric antibiotic use in the early phase of hospitalized patients with COVID-19: Results from a multicentre retrospective cohort study in the Netherlands,” Infectious Diseases, vol. 53, no. 2, pp. 102–110, 2021. [Online]. Available: https://doi.org/10.1080/23744235.2020.1839672
B. J. Langford et al., “Bacterial co-infection and secondary infection in patients with COVID-19: A living rapid review and meta-analysis,” Clinical Microbiology and Infection, vol. 26, no. 12, pp. 1622–1629, 2020. [Online]. Available: https://doi.org/10.1016/j.cmi.2020.07.016
Ministry of Health of the Republic of Indonesia, Decree of the Minister of Health of the Republic of Indonesia No. HK.01.07/MENKES/5671/2021 on Clinical Management of Coronavirus Disease 2019 (COVID-19) in Health Care Facilities. Jakarta, Indonesia: Ministry of Health of the Republic of Indonesia, 2021. [Online]. Available: https://peraturan.bpk.go.id/Details/171647/keputusan-menkes-no-hk0107menkes56712021
L. Lansbury, B. Lim, V. Baskaran, and W. S. Lim, “Co-infections in people with COVID-19: A systematic review and meta-analysis,” Journal of Infection, vol. 81, no. 2, pp. 266–275, 2020. [Online]. Available: https://doi.org/10.1016/j.jinf.2020.05.046
World Health Organization, 2021 AWaRe Classification. Geneva, Switzerland: World Health Organization, 2021. [Online]. Available: https://www.who.int/publications/i/item/2021-aware-classification
R. Limato et al., “Optimizing antibiotic use in Indonesia: A systematic review and evidence synthesis to inform opportunities for intervention,” medRxiv, 2022. [Online]. Available: https://doi.org/10.1101/2022.02.20.22271261
L. Herliyana, A. Purnamayanti, and F. O. H. Prasetyadi, “Delivering a birth safely: Case reports of perineal infection prevention among pregnant women living around ex-landfills,” Jurnal Farmasi dan Ilmu Kefarmasian Indonesia, vol. 9, no. 2, pp. 131–137, 2022. [Online]. Available: https://doi.org/10.20473/jfiki.v9i22022.131-137
A. Dahesihdewi and Y. N. Fanani, “SG-APSIC1074: Trend of ‘ESKAPE’ and their susceptibility changes for meropenem and levofloxacin during the pandemic at Sardjito Hospital, Yogyakarta, Indonesia,” Antimicrobial Stewardship & Healthcare Epidemiology, vol. 3, suppl. 1, 2023. [Online]. Available: https://doi.org/10.1017/ash.2023.7
Y. R. Saharman, A. Karuniawati, J. A. Severin, and H. A. Verbrugh, “Infections and antimicrobial resistance in intensive care units in lower-middle income countries: A scoping review,” Antimicrobial Resistance & Infection Control, vol. 10, art. no. 22, 2021. [Online]. Available: https://doi.org/10.1186/s13756-020-00871-x
Ministry of Health of the Republic of Indonesia, Regulation of the Minister of Health of the Republic of Indonesia No. 8 of 2015 on the Antimicrobial Resistance Control Program in Hospitals. Jakarta, Indonesia: Ministry of Health of the Republic of Indonesia, 2015. [Online]. Available: https://farmalkes.kemkes.go.id/unduh/permenkes-8-2015/
J. P. Metlay et al., “Diagnosis and treatment of adults with community-acquired pneumonia: An official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America,” American Journal of Respiratory and Critical Care Medicine, vol. 200, no. 7, pp. e45–e67, 2019. [Online]. Available: https://doi.org/10.1164/rccm.201908-1581ST
A. Bhimraj et al., “Infectious Diseases Society of America guidelines on the treatment and management of patients with COVID-19,” Clinical Infectious Diseases, vol. 78, no. 7, pp. e250–e349, 2024. [Online]. Available: https://doi.org/10.1093/cid/ciae121
M. S. Pulia et al., “National trends in antibiotic prescribing for adults hospitalized with coronavirus disease 2019 and other viral respiratory infections,” Open Forum Infectious Diseases, vol. 12, no. 2, art. no. ofaf045, 2025. [Online]. Available: https://doi.org/10.1093/ofid/ofaf045
J. H. Beigel et al., “Remdesivir for the treatment of Covid-19: Final report,” The New England Journal of Medicine, vol. 383, no. 19, pp. 1813–1826, 2020. [Online]. Available: https://doi.org/10.1056/NEJMoa2007764
World Health Organization, Therapeutics and COVID-19: Living Guideline, August 2025. Geneva, Switzerland: World Health Organization, 2025. [Online]. Available: https://www.who.int/publications/i/item/B09540
K. McCarthy, “Oral or intravenous antibiotics?,” Australian Prescriber, vol. 43, no. 2, pp. 45–48, 2020. [Online]. Available: https://doi.org/10.18773/austprescr.2020.008
D. C. Funder and D. J. Ozer, “Evaluating effect size in psychological research: Sense and nonsense,” Advances in Methods and Practices in Psychological Science, vol. 2, no. 2, pp. 156–168, 2019. [Online]. Available: https://doi.org/10.1177/2515245919847202
G. M. Bwire, “Coronavirus: Why men are more vulnerable to COVID-19 than women?,” SN Comprehensive Clinical Medicine, vol. 2, pp. 874–876, 2020. [Online]. Available: https://doi.org/10.1007/s42399-020-00341-w
A. Pradhan and C. Olsson, “Sex differences in severity and mortality from COVID-19: Are males more vulnerable?,” Biology of Sex Differences, vol. 11, art. no. 53, 2020. [Online]. Available: https://doi.org/10.1186/s13293-020-00330-7
N. J. Atallah et al., “Baseline procalcitonin as a predictor of bacterial infection and clinical outcomes in COVID-19: A case-control study,” PLOS ONE, vol. 17, no. 1, art. no. e0262342, 2022. [Online]. Available: https://doi.org/10.1371/journal.pone.0262342
J. H. Bae, “COVID-19 and diabetes mellitus: From pathophysiology to clinical management,” Nature Reviews Endocrinology, vol. 17, pp. 11–30, 2021. [Online]. Available: https://doi.org/10.1038/s41574-020-00435-4
A. Asyriva et al., “Quantity of antibiotic use and its association with clinical outcomes in COVID-19 patients: A snapshot from a provincial referral hospital in Indonesia,” Narra J, vol. 3, no. 3, art. no. e272, 2023. [Online]. Available: https://doi.org/10.52225/narra.v3i3.272
T. J. VanderWeele, “Principles of confounder selection,” European Journal of Epidemiology, vol. 34, pp. 211–219, 2019. [Online]. Available: https://doi.org/10.1007/s10654-019-00494-6
R. J. Desai and J. M. Franklin, “Alternative approaches for confounding adjustment in observational studies using weighting based on the propensity score: A primer for practitioners,” BMJ, vol. 367, art. no. l5657, 2019. [Online]. Available: https://doi.org/10.1136/bmj.l5657
T. P. Asmarawati et al., “The clinical impact of bacterial co-infection among moderate, severe and critically ill COVID-19 patients in Indonesia,” F1000Research, vol. 10, art. no. 113, 2025. [Online]. Available: https://doi.org/10.12688/f1000research.31645.2
C. Michailides et al., “Impact of bacterial infections on COVID-19 patients: Is timing important?,” Antibiotics, vol. 12, no. 2, art. no. 379, 2023. [Online]. Available: https://doi.org/10.3390/antibiotics12020379
DOI: https://doi.org/10.37311/ijpe.v6i2.39488
Refbacks
- There are currently no refbacks.
Copyright (c) 2026 Fifin Oktaviani Oktaviani, Heldi Candra
Indonesian Journal of Pharmaceutical Education is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.